A Swiss microbiota company with two technology platforms: ApyraVax for innovative mucosal vaccines against enteric infections; ApyraMed for live modified biotherapeutics with 2 lead products with indication in cancer immunotherapy of solid tumors and dysbiosis by antibiotics and unhealthy diet.